Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes | Zendy

Luigi Gennari | Zendy; Daniela Merlotti | Zendy; Roberto Valenti | Zendy; Elena Ceccarelli | Zendy; Martina Ruvio | Zendy; Maria G. Pietrini | Zendy; Cosimo Capodarca | Zendy; Maria Beatrice Franci | Zendy; Maria Stella Campagna | Zendy; Anna Rita Calabrò | Zendy; Dorica Cataldo | Zendy; Konstantinos Stolakis | Zendy; Francesco Dotta | Zendy; Ranuccio Nuti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes

Author(s) -

Luigi Gennari,

Daniela Merlotti,

Roberto Valenti,

Elena Ceccarelli,

Martina Ruvio,

Maria G. Pietrini,

Cosimo Capodarca,

Maria Beatrice Franci,

Maria Stella Campagna,

Anna Rita Calabrò,

Dorica Cataldo,

Konstantinos Stolakis,

Francesco Dotta,

Ranuccio Nuti

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2958

Subject(s) - sclerostin , medicine , endocrinology , bone remodeling , osteoblast , diabetes mellitus , type 2 diabetes mellitus , body mass index , wnt signaling pathway , chemistry , biochemistry , in vitro , gene

Previous observations showed a condition of low bone turnover and decreased osteoblast activity in both type 1 and 2 diabetes mellitus (DM1 and DM2). Sclerostin is a secreted Wnt antagonist produced by osteocytes that regulates osteoblast activity and thus bone turnover. Its levels increase with age and are regulated by PTH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research